drugset / Trial / NCT04396340
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.
Timeline
- Start
- 2020-05-11
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
Outcome
Outcome not reported
Stopped: “discontinued development program”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | XMT-1592 | Other / unclassified | — | Intravenous |